Incidence and consequences of bone metastases in lung cancer patients
Open Access
- 1 February 2013
- journal article
- research article
- Published by Elsevier in Journal of Bone Oncology
- Vol. 2 (1) , 22-29
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Mechanisms and treatment of hypercalcemia of malignancyCurrent Opinion in Endocrinology, Diabetes and Obesity, 2011
- Impact of New Chemotherapeutic and Targeted Agents on Survival in Stage IV Non-Small Cell Lung CancerThe Oncologist, 2011
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective AnalysisThe Oncologist, 2011
- Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastasesBMC Urology, 2010
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyJournal of Clinical Oncology, 2010
- The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in SpainEuropean Journal of Cancer Care, 2009
- Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast ActivityJournal of Thoracic Oncology, 2008
- Predictors of Survival in Patients With Bone Metastasis of Lung CancerClinical Orthopaedics and Related Research, 2008